Hydrogel Particle Implants for Sustained Ocular Drug Release
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing drug delivery systems face challenges in optimizing drug release profiles and ensuring biocompatibility, particularly in confined spaces like the eye, where large drug concentrations are desired while minimizing system volume.
Innovation Solution
The development of covalently-crosslinked hydrogel particles with a surrounding hydrogel coating that controls drug release rates and enhances biocompatibility by using specific precursor materials and structural designs to create a sustained release system.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If large drug concentrations are used to achieve therapeutically effective dosage, then the therapeutic efficacy is improved, but the system volume increases which is problematic in confined spaces like the eye
Solution Approach 1:
The drug delivery system is segmented into multiple small hydrogel particles instead of a single large reservoir. Each particle contains therapeutic agents dispersed in a hydrogel matrix, allowing the system to achieve high drug concentration through particle aggregation rather than volume expansion. The particles can be administered as a suspension that distributes throughout the target tissue space.
Solution Approach 2:
The invention employs a nested structure where hydrogel particles are embedded within a larger hydrogel matrix or coating. This nested arrangement allows concentrated drug-loaded particles to be contained within a minimal-volume delivery vehicle that can be injected into confined spaces, effectively nesting the high-concentration drug reservoir within a compact delivery system.
2Productivity
If drug release rate is increased to achieve rapid therapeutic effect, then the therapeutic efficacy is improved, but the duration of action is reduced
Solution Approach 1:
The hydrogel matrix provides dynamic drug release control where the release rate adapts to physiological conditions. The hydrogel's mesh size, swelling behavior, and degradation rate dynamically adjust based on local pH, temperature, and enzymatic conditions, enabling the system to provide high initial release rates when drug concentration is critical while automatically extending the release duration as conditions change.
Solution Approach 2:
The invention utilizes parameter changes in the hydrogel's physical and chemical properties to control drug release kinetics. By adjusting crosslinking density, hydrophilicity, and degradation rate of the hydrogel matrix, the system can be tuned to provide rapid initial release followed by sustained release, effectively changing release parameters over time to match therapeutic requirements.
3Ease of manufacture
If foreign materials are used to create the implant system, then the manufacturing flexibility is improved, but the immune response increases reducing biocompatibility
Solution Approach 1:
The invention changes the material parameter from synthetic foreign materials to biocompatible natural or bio-inspired materials such as hyaluronic acid, collagen, or gelatin-based hydrogels. These materials maintain manufacturing flexibility through controlled crosslinking and formulation while fundamentally altering the material's interaction with the immune system to reduce rejection and inflammation responses.
Solution Approach 2:
The invention converts the potential harm of foreign material recognition by the immune system into a benefit by using materials that the body naturally recognizes and tolerates. By selecting biomaterials that mimic natural extracellular matrix components, the system turns what would be a harmful immune response into a beneficial biocompatibility feature, allowing the implant to integrate seamlessly with surrounding tissue.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The system achieves controlled drug release with minimal volume and improved biocompatibility, reducing immune response and optimizing therapeutic efficacy in sensitive environments.
Implementation Method 1
hydrogel particles having therapeutic agents that are disposed in a surrounding hydrogel
Implementation Method 2
covalently-crosslinked hydrogel particles
Data Source
AI summary
Materials and methods for treating a patient, optionally a patient with an eye disease, comprising providing a collection of particles that comprise a first biodegradable material that is a hydrogel or a xerogel and a therapeutic agent, with the first material, before biodegradation, having a rate of release for the therapeutic agent as measured in physiological solution, and forming a second hydrogel ex vivo or in situ on a tissue of the patient at a site of intended use, optionally at or near an eye, that at least partially coats the collection of particles. The agent is released to treat the patient.